Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cardiogen

AEDR, H-Ala-Glu-Asp-Arg-OH

Quick Stats
Studies 54
Trials 4
Score 1
2021 pubmed 34 citations

Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.

Schwartz. Peter J PJ; Moreno. Cristina C; Kotta. Maria-Christina MC; Pedrazzini. Matteo M; Crotti. Lia L; Dagradi. Federica F; Castelletti. Silvia S; Haugaa. Kristina H KH; Denjoy. Isabelle I; Shkolnikova. Maria A MA; Brink. Paul A PA; Heradien. Marshall J MJ; Seyen. Sandrine R M SRM; Spätjens. Roel L H M G RLHMG; Spazzolini. Carla C; Volders. Paul G A PGA

Key Findings

  • The p.A341V mutation leads to the longest QT intervals and highest symptom rate among LQT1 patients.
  • Mutations near p.A341V in the KCNQ1 S6 segment also increase arrhythmic risk, though less severely.
  • Loss of PKA‑dependent stimulation of the IKs channel explains why p.A341V is especially harmful.

Practical Outcomes

  • For most biohackers, the main takeaway is that genetic testing for KCNQ1 mutations can identify higher heart‑rhythm risk, but there are no direct lifestyle or supplement protocols suggested. Knowing one's mutation status may guide medical monitoring rather than self‑directed interventions.

Summary

The study looked at a specific heart gene (KCNQ1) and found that a mutation called p.A341V makes people more likely to have dangerous heart rhythm problems, while nearby mutations also raise risk but not as much. The severity is linked to how these mutations affect the heart's electrical channel regulation.

Abstract

Mutation type, location, dominant-negative IKs reduction, and possibly loss of cyclic adenosine monophosphate (cAMP)-dependent IKs stimulation via protein kinase A (PKA) influence the clinical severity of long QT syndrome type 1 (LQT1). Given the malignancy of KCNQ1-p.A341V, we assessed whether mutations neighbouring p.A341V in the S6 channel segment could also increase arrhythmic risk. Clinical and genetic data were obtained from 1316 LQT1 patients [450 families, 166 unique KCNQ1 mutations, including 277 p.A341V-positive subjects, 139 patients with p.A341-neighbouring mutations (91 missense, 48 non-missense), and 900 other LQT1 subjects]. A first cardiac event represented the primary endpoint. S6 segment missense variant characteristics, particularly cAMP stimulation responses, were analysed by cellular electrophysiology. p.A341-neighbouring mutation carriers had a QTc shorter than p.A341V carriers (477 ± 33 vs. 490 ± 44 ms) but longer than the remaining LQT1 patient population (467 ± 41 ms) (P < 0.05 for both). Similarly, the frequency of symptomatic subjects in the p.A341-neighbouring subgroup was intermediate between the other two groups (43% vs. 73% vs. 20%; P < 0.001). These differences in clinical severity can be explained, for p.A341V vs. p.A341-neighbouring mutations, by the p.A341V-specific impairment of IKs regulation. The differences between the p.A341-neighbouring subgroup and the rest of LQT1 mutations may be explained by the functional importance of the S6 segment for channel activation. KCNQ1 S6 segment mutations surrounding p.A341 increase arrhythmic risk. p.A341V-specific loss of PKA-dependent IKs enhancement correlates with its phenotypic severity. Cellular studies providing further insights into IKs-channel regulation and knowledge of structure-function relationships could improve risk stratification. These findings impact on clinical management.

Study Information

Provider

pubmed

Year

2021

Date

2021-12-07T00:00:00.000Z

DOI

10.1093/eurheartj/ehab582

Citations

34

References

57